Search for: "Deas v. Deas" Results 1 - 20 of 758
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
15 May 2022, 9:11 pm by The Regulatory Review Staff
The Regulatory Review would like to thank the members of the 2021-2022 editorial board for their passion and hard work in producing this publication. [read post]
7 Dec 2021, 5:09 am by Charles Sartain
  Answer: As many as they want, but the court will only use one, says King Operating et al v. [read post]
17 Sep 2021, 12:00 pm by Caitlin Lentz
  While the PHE continues, the exception will apply and provides as follows: “DEA-registered practitioners in all areas of the United States may issue prescriptions for all schedule II-V controlled substances to patients for whom they have not conducted an in-person medical evaluation, provided all of the following conditions are met: The prescription is issued for a legitimate medical purpose by a practitioner acting in the usual course of his/her professional… [read post]
17 Sep 2021, 12:00 pm by Caitlin Lentz
  While the PHE continues, the exception will apply and provides as follows: “DEA-registered practitioners in all areas of the United States may issue prescriptions for all schedule II-V controlled substances to patients for whom they have not conducted an in-person medical evaluation, provided all of the following conditions are met: The prescription is issued for a legitimate medical purpose by a practitioner acting in the usual course of his/her professional… [read post]
10 Sep 2021, 7:33 am by Rebecca Tushnet
C2R also advertised that its products meet DEA disposal standards by making drugs “scientifically irretrievable. [read post]